サポート 抗体業界の動向 Week 5, Apr 2024: Immunosenescence

Week 5, Apr 2024: Immunosenescence

Biointron 2024-04-30 Read time: 3 mins
immunosenescence.jpg
DOI: 10.3389/fimmu.2020.579220

As we age, our innate and adaptive immune system undergoes various changes, typically characterized by decreased lymphopoiesis and adaptive immunity, and increased inflammation and myeloid pathologies. Immunosenescence (the gradual deterioration of the immune system associated with ageing), makes individuals more susceptible to infections, less responsive to vaccines, and prone to the development of chronic inflammatory conditions and autoimmune diseases. Additionally, age-related alterations in the composition and function of the microbiota, the community of microorganisms living in and on the body, can further influence immune function and contribute to the overall ageing process.

This month, several papers related to antibodies and aging were published, including a comprehensive review by Quiros-Roldan et al., studying the impact of immune system aging on infectious diseases, including the progressive reduction of the body’s ability to trigger effective antibody responses. Here they describe the increased public interest in immune system aging due to prolonged life expectancy, contrasted to health expectancy. They also provide an analysis of the immune players involved, in addition to immune cells/mediators within endogenous and exogenous factors and co-morbidities.

Another paper this month provides insight into why age is a major risk factor for severe COVID-19. By evaluating the impact of aging and anti-IFN autoantibodies on host immune response in the blood, upper airway, and nasal microbiome, the researchers found that older age correlated with impaired viral clearance, dysregulated immune signaling, and persistent and potentially pathologic activation of pro-inflammatory genes and proteins.

Ending on a bright note, Ross et al.’s study in Nature demonstrates the antibody-mediated depletion of my-haematopoietic stem cells (HSCs) in aged mice restores characteristic features of a more youthful immune system. Their findings show it might be possible to reverse the ageing phenotype by eliminating my-HSCs in aged mice and contributes to the understanding and intervention of diseases exacerbated or caused by dominance of the haematopoietic system by my-HSCs.

Subscribe to our 抗体業界の動向

Recent 抗体業界の動向

This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year

Jul 01, 2024
抗体業界の動向

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Apr 07, 2024
抗体業界の動向

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-

Dec 24, 2024
抗体業界の動向

The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

Dec 17, 2024
抗体業界の動向

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。